| Status: In progress | |
Treatment of chronic hepatitis C (HCV) in patients from 3 years of age to less than 18 years of age. |
|
Medicine details |
|
| Medicine name | sofosbuvir/velpatasvir (Epclusa®) |
| Formulation | 150 mg/37.5 mg coated granules, 200 mg/50 mg coated granules |
| Reference number | 4573 |
| Indication | As above |
| Company | Gilead Sciences Ltd |
| BNF chapter | Infections |
| Submission type | Licence extension for paediatric use |
| Status | In progress |
| AWMSG meeting date | 08/02/2023 |
| Date of issue | TBC |